Rituximab, a genetically engineered monoclonal chimeric antibody, targets the @entity2225 antigen expressed on B cells. It was approved by the US Food and Drug Administration on November 26, 1997, for the indication of relapsed or refractory, @entity2225 -positive, B-cell, low-grade or @entity1893 (LG/F @entity1893 ), and by the European Agency for the Evaluation of Medicinal Products on June 2, 1998, for therapy of @entity1 with Stage III/IV, follicular, chemoresistant or relapsed @entity1893 . Eight Phase II or II clinical trials in LG/F @entity1893 @entity1 have been completed: five single-agent studies and three combination studies. @entity2408 has a favorable safety profile: most adverse events (AEs) are Grade 1 or 2, and the frequency of AEs decrease with subsequent infusions. AEs in the combination studies are consistent with those seen with individual agents. For evaluable @entity1 in the single-agent studies, overall response rates (ORR) ranged from 40% to 60%, median duration of response (DR) ranged from 5.9 to 15.0+ months, and median @entity1054 ( @entity1054 ) ranged from 8.1 to 19.4+ months. For evaluable @entity1 in the combination studies, the ORR ranged from 45% to 100%, median DR ranged from 11.7+ to 39.1+ months, and median @entity1054 ranged from 12.9+ to 40.5+ months. Studies in intermediate- and high-grade @entity1893 are ongoing. Long-term development plans include evaluating the safety and efficacy of rituximab in various types of @entity706 and in combination with other @entity706 regimens. Future studies may explore ways to increase rituximab efficacy by upregulating @entity2225 or increasing effector function with different cytokines.

Rituximab: the first monoclonal antibody approved for the treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2408 :: ('CHEBI:64357', 'Chemical') :: ['Rituximab'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma'] @entity2225 :: ('54474', 'Gene') :: ['CD20'] @entity1893 :: ('MESH:D008228', 'Disease') :: ["follicular non-Hodgkin's lymphoma", 'NHL'] @entity1054 :: ('MESH:D000377', 'Disease') :: ['TTP', 'time to progression']
@entity706 :: (MESH:D008223,Disease) :: ['lymphoma']
